Telix Pharmaceuticals Ltd. (TLX) witnessed a remarkable surge of 9.88% in its stock price during the pre-market trading session on Friday. This upward movement can be attributed to the company's stellar financial performance for the fiscal year 2024, as reported in its recent earnings call.

Telix Pharmaceuticals demonstrated an impressive 56% year-over-year increase in revenue, surpassing its guidance. The company's adjusted EBITDA saw a substantial 70% improvement, reaching $99 million, reflecting its operational efficiency and profitability. Furthermore, Telix Pharmaceuticals reported an 80% improvement in operating cash inflow, showcasing its strong cash generation capabilities.

One of the most notable achievements was the staggering 860% increase in profit after tax, highlighting the company's ability to convert revenue into substantial profitability. Telix Pharmaceuticals ended the fiscal year with a robust cash position of $710 million, bolstered by a strategic convertible bond placement, providing ample liquidity for future growth initiatives and investments in its therapeutic pipeline.